Drug Type T cell engagers (TCE) |
Synonyms BHB299 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CEACAM6 inhibitors(Carcinoembryonic antigen related cell adhesion molecule 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | United States | 20 Apr 2026 |






